

Int Poster J Dent Oral Med 2004, Vol 6 No 01, Poster 211

International Poster Journal

GTR with bioabsorbable barriers: Long-term results

Language: English

Authors:

Diana Krigar, Bernadette Pretzl, DDS Dr. Dr. Ti-Sun Kim, Dr. Christof Dörfer, Dr. Harald Steinbrenner, Prof. Dr. Peter Eickholz Departement of Operative Dentistry and Periondontology, Clinic of Dental Medicine, University Clinic of Heidelberg Germany

IP

Date/Event/Venue:

June 18-22th, 2003 Europerio 4 Berlin/Germany

Objectives

Evaluation of the long-term results after GTR therapy of infrabony defects using 2 different bioabsorbable barriers after 5 years.

Material and Methods

Patients:

- 15 patients (3 male, 12 female) 22 to 64 years of age.
- untreated severe periodontitis.
- 15 pairs of contralateral infrabony defects.

Radiographic examination

- At baseline, 12, and 60 ± 3 months after GTR-therapy: standardized radiographs of all teeth with infrabony defects with modified film holders (VIP 2 film Positioning, UpRad Corp., Fort Lauderdale, FL, USA).
- Intraoral dental radiographs (Ultra-speed, Eastman Kodak Co., Rochester, NY, USA), size 2 film.
- X-ray source (Heliodent 70, 70 kV, 7 mA, Siemens, Bensheim, Germany).
- Development unit (Periomat, Dürr Dental GmbH, Bietigheim-Bissingen, Germany).

Clinical examinations:

at baseline, 12, and 60 \pm 3 months after GTR-therapy at 6 sites per tooth:

- Gingival (GI) and Plaque Index (PII).
- PD and PAL-V to the nearest 0.5mm (PCPUNC 15; Hu Friedy, Chicago, USA).

Periodontal surgery: GTR therapy:

- 15 defects: polydioxanone barrier (Mempol, Ethicon, Norderstedt, Germany); test group.
- 15 defects: polylactide acetyltributyl citrate barrier (Guidor, Guidor AB, Huddinge, Sweden); control group.

Radiographic measurements:

- Digitization of all radiographs with a flatbed scanner (Linotype Saphir, Friadent AG, Mannheim, Germany) with a resolution of 600 x 1200 dpi.
- All further measurements were made using a computer program (Friacom 2.5, Friadent AG, Mannheim, Germany): with 9.5x magnification.
- Marking of the ends of the maxillary wire on the radiographs and entering of its actual length. All further measurements were
 adjusted automatically for magnification.
- Measurement of the distances CEJ-BD (Figs. 1, 2).



Fig. 1 a, b, c: standardized radiographs of an infrabony defect mesial 45 at baseline (a), 12 (b), and 60 months (c) after GTRtherapy with a polydioxanone barrier: CEJ (cemento-enamel junction), BD (most apical extension of bony defect). Fig. 2 a, b, c: standardized radiographs of an infrabony defect distal 35 at baseline (a), 12 (b), and 60 months (c) after GTR-therapy

an infrabony defect distal 35 at baseline (a), 12 (b), and 60 months (c) after GTR-therapy with a polylactide acetyltributyl citrate barrier: CEJ (cemento-enamel junction), BD (most apical extension of bony defect). Definition of landmarks: If the CEJ was destroyed by a restoration, its margin was taken as reference. BD: the most coronal point where the periodontal ligament space showed continuous width. If no periodontal ligament space was identified, the point where the projection of AC crossed the root surface was taken as the landmark. If both structures could be identified at one defect, the point defined by the periodontal ligament was used as BD. If several bony contours could be identified, the most apical point that crossed the rootsurface was defined as BD (Figs. 1, 2).

• All radiographic measurements were performed by two examiners blinded to the clinical measurements and repeated after 7 days: DK and BP. To reduce error the means of all 4 measurements were entered into analysis.

Statistical analysis:

- Statistical unit: patient
- Kolmogorov-Smirnov/ Lilliefors-test for normal distribution.
- Comparison of clinical and radiographic parameters from baseline to 12 and 60 months after surgery and between test and control with paired t tests.

Results

Results I

- 13 of 15 patients were available for the 60-months re-examination: 1 patient did not reappear for the 60 months reexamination, 1 patient deceased after the 12 months re-examination.
- PII and GI at baseline, 12, and 60 months after surgery are given in Tab. 1 and 2.
- Both groups showed a statistically significant PD reduction (P < 0.001), PAL-V gain ($P \le 0.001$), and bony fill 12 and 60 months after surgery (Tab. 4, 5, 7).
- Both groups showed a statistically significant PAL-V loss from 12 to 60 months (P < 0.05) (Tab. 5).
- 60 months after GTR therapy 3 defects in the control group and 1 in the test group had PAL-V loss ≥ 3 mm compared to the 12 months re-examination.
- The study failed to show statistically significant differences between test and control group regarding PD reduction, PAL-V gain, and bony fill 12 and 60 months after surgery.

Results II

Polylactide Polydioxanone Difference P

```
Baseline
            0.23 \pm 0.60 \ 0.08 \pm 0.28
                                         0.15 \pm 0.38 \quad 0.157
12 months 0.62 \pm 0.87 \ 0.46 \pm 0.78
                                         0.15 \pm 0.99 \quad 0.516
Change
            0.39 \pm 0.96 \ 0.39 \pm 0.65 0.00 \pm 1.23 \ 1.000
            0.131
                         0.059
P
60 months 0.39 \pm 0.77 \ 0.46 \pm 0.78
                                         -0.08 ± 0.28 0.317
            0.15 \pm 1.07 \ 0.39 \pm 0.87
                                        -0.23 ± 0.44 0.083
Change
            0.581
Ρ
                         0.129
Tab. 1: Plaque Index (n=13).
```

```
Polylactide Polydioxanone Difference
Baseline
           1.54 \pm 0.88 \quad 1.69 \pm 0.75
                                       -0.15 ± 0.55 0.317
12 months 0.31 \pm 0.75 0.39 \pm 0.77
                                        -0.08 ± 1.04 0.705
Change
           -1.23 \pm 1.01 - 1.31 \pm 0.95 - 0.08 \pm 1.19 0.888
           0.005
                         0.004
Ρ
60 months 1.15 \pm 0.99 0.46 \pm 0.89
                                        0.69 \pm 0.95 \quad 0.034
Change
           -0.39 \pm 1.61 - 1.23 \pm 1.30 - 0.85 \pm 1.28 0.039
           0.441
                         0.011
Р
Tab. 2: Gingival Index (n=13)
```

```
Polylactide Polydioxanone Difference
                                                        Ρ
           7.35 \pm 1.94 7.31 \pm 1.20
Baseline
                                         0.04 \pm 1.80 \quad 0.94
12 months 2.42 \pm 0.91 3.15 \pm 1.35
                                         0.15 \pm 0.99 \quad 0.046
Change
           -4.92 \pm 2.01 - 4.15 \pm 1.56 \quad 0.00 \pm 1.23 \quad 0.211
P
            < 0.001
                          < 0.001
95% Confidence Interval
                                          -2.04 \pm 0.50
60 months 3.39 ± 1.12 3.69 ± 1.49
                                         -0.31 ± 1.38 0.436
Change
           -3.96 \pm 1.34 \ 3.62 \pm 1.61
                                         -0.35 ± 1.81 0.503
            < 0.001
                          < 0.001
P
95% Confidence Interval
                                         0.75 \pm 1.44
           0.96 \pm 1.16 \quad 0.54 \pm 1.68
                                         0.42 \pm 2.05 \quad 0.471
Change
12-60 months
P
           0.001
                          0.269
95% Confidence Interval
                                         -0.82 \pm 1.66
Tab. 4: Probing Depth (n=13).
```

	Polylactide	Polydioxanone	Difference	Ρ
Baseline	8.35 ± 1.61	8.31 ± 1.32	0.04 ± 1.20	0.910
12 months	4.35 ± 1.70	4.85 ± 1.56	-0.50 ± 1.53	0.261
Change	4.00 ± 0.91	3.46 ± 1.52	0.54 ± 1.69	0.273
Ρ	< 0.001	< 0.001		
95% Confid	dence Interva	I	-1.59 ± 0.33	
60 months	5.96 ± 1.87	6.08 ± 2.17	-0.12 ± 1.70	0.811
Change	2.39 ± 1.00	2.23 ± 1.80	0.15 ± 1.85	0.770
Ρ	< 0.001	0.001		
95% Confidence Interval			-0.97 ± 1.27	
Change	-1.62 ± 1.06	-1.23 ± 1.93	-0.39 ± 2.24	0.547
12-60 mon	ths			
Ρ	< 0.001	< 0.040		
95% Confid	dence Interva	I	-1.74 ± 0.97	
Tab. 5: Ve	rtical Probing	Attachment Le	vel (n=13).	

	Polylactide		Polydioxan	one
PAL-V	12 months	60 months	12 months	60 months
≤ 2 mm	1	6	3	8
> 2 - ≤ 4 mm	9	7	6	3
>4 - ≤6 mm	3	-	4	2
> 6 mm	-	-	-	-

Tab. 6: Distribution of Vertical Probing Attachment Gain.

	Polylactide	Polydioxanone	Difference	Ρ
Baseline	9.35 ± 2.99	8.86 ± 2.56	0.50 ± 2.27	0.443
12 months	8.41 ± 2.75	7.70 ± 2.80	0.71 ± 2.21	0.272
Change	0.94 ± 1.41	1.15 ± 1.31	-0.21 ± 1.89	0.697
Ρ	< 0.05	< 0.01		
60 months	8.33 ± 3.12	7.31 ± 3.18	1.01 ± 2.77	0.213
Change	1.03 ± 1.63	1.54 ± 2.19	-0.51 ± 2.83	0.527
Р	< 0.05	< 0.05		

Tab. 7: Distance Cemento-enamel Junction (CEJ) to Bony Defect (BD) (n=13).

Discussion and Conclusions

- There are no statistically significant differences regarding PD reduction, PAL-V gain, and bony fill after GTR therapy using polylactide acetyltributyl citrate or polydioxanone.
- PAL-V gain after GTR therapy in infrabony defects using both bioabsorbable barriers was stable after 5 years in 21 of 26 defects (81%).
- PAL-V gain achieved by GTR therapy using bioabsorbable membranes may be maintained up to 5 years successfully.

This Poster was submitted by Diana Krigar.

Correspondence address:

Diana Krigar Section of Periodontology Departement of Operative Dentistry and Periodontology Im Neuenheimer Feld 400 69120 Heidelberg Germany



There are no statistically significant differences reg PAL-V gain, and bony fit after GTR therap acetyliributyl citrate or polydioxanone.

PAL-V gain achieved by GTR therapy using bit may be maintained up to 5 years successfully

	0 2510.00	6.08+0.28	and the second second	0.167
12 monite Change	0.59+0.95	8.45:0 75 5.39+0 55	0.15:0.18 0.15:0.99 0.09:1.23	0.516
p.	0.131	0.059		
60 months		0.45-0.78	-0.08:0 28	0.317
Change	6 1511.07	0.3910 87	- 0123+0.44	0.063
	0.581	0.129		
Tats 3 Gin				
	Polytacside	Polydicesna	te Difference	
Besetine 12 months	1.54:0.88	1.69+0.75	-0.15-0.55 -0.05-1.04 -0.08-1.19	0.31
Change	0.31+0.75	-1.31:0.55	0.0001100	0.85
Cumular.	0.005	0.004	-water.ip	
60 marilhs	1.15-5.99	0 48+0 89	645-855	0.83
Change	-0.38-1.61	-1.2311.10	0.05-0.05	0.63
P	0.441	0.011		
	NAME OF COLUMN		and the second	
TAD, 4 Pro	Polylacticle 7.25:1.94	14 13). Datation Prove	-	-
Baseline	7 35-1 94	Polydioxanor 7 31+1-35	0.0411.60	0.94
12 months	2.4210.91	3 15±1.35	0.15:10.59	0.94
Change	4.92-2.01	-4.15:1.56	6.00+1.33	0.31
P	< 0.001	- 0.001		
85% Canfid	dence Interva		-2 04-3 50	
60 months	3.39:1.12	3.6011.48	-0.3111.38	0.43
P	× 0.001	< 0.001		
HONG COMPL	dence kiterika Stasici. KG	California -	8,75-1.44	
Change.	2005121.06			
12:60 men				
and the second	9.001	0.269	Alter de	
89% Carni			0.82.1.66	
Tab 5 Ver Baseline	tical Proteig Polylactica 6 35-1 61	Attactoreent L Polydiasaror 8 31±1 32	Difference	0.91
Tab. 5: Ver Baseline 12 months	Lical Probeng Polylactide 6 35-1 61 4 35-1 70	Attactoreen L Polydiaxarar 8.51±1.32 4.65±1.56		0.91
Tab. 5: Ver Baseline 12 reprints Change	Lical Probing Polylacticle 6.35-1.61 4.35-1.70 4.00-0.91	Artachineser L Polydiacaror 8.31±1.32 4.85±1.55 3.46±1.52	Difference	0.91
Tab. 5: Ver Baseline 12 menths Charige P	11031 Probing Polylacticle 6.35-151 4.35:170 4.00:0 91 < 5.001	Attornation Polydiasaro 8 31:1 32 4 05:1 54 3 40:1 52 * 0 501	 Difference Difference 0.64±1.20 -0.50±1.53 0.54±1.69 	0.91
Tab. 5: Ver Baseline 12 months 12 months Change P	11631 Probing Polylactide 6.35-1.61 4.35:1.70 4.00:0.91 4.00:1 dence Interne	Attached Polydiacaro 8 51:1 32 4 65:1 54 3 46:1 52 * 0 501		0.25
Tab. 5: Ver Basetine 12 months Change p 95% Confu	Polytacticle 6.35-1.61 4.35-1.70 4.00:0.91 < 8.001 dence Interne 5.26-1.87	Attaches Polydiasaro 8 31±1 32 4 85:1 55 3 46:1 52 * 0 501 1 6 66:2 17		0.91 0.25 0.27 0.27
Tab. 3: Ver Baseline 12 menths Change 9 55% Cenths 60 menths 60 menths	Polytacticle 6.35-1.61 4.35-1.70 4.00:0.91 < 8.001 dence Interne 5.26-1.87	Attaches Polydiasaro 8 31±1 32 4 85:1 55 3 46:1 52 * 0 501 1 6 66:2 17		0.91 0.25 0.27 0.27
Tab. 3: Ver Baseline 12 menths Change 9 55% Cenths 60 menths 60 menths 60 menths 60 menths	11(3) Proteing Polytacticle 6.35:1.61 4.35:1.70 4.35:1.70 4.30:0.91 4.00:1 dense triterie 5.96:1.87 2.39:1.00 4.001	Artoniaatio B 31::1 32 4 05::1 52 4 05::1 52 + 0.501 4 06:2 17 2::21::1 50 0.001	 Difference 0.64±1.20 0.54±1.80 0.54±1.83 0.54±1.83 0.12±1.70 0.15±1.84 	0.91 0.25 0.27 0.27
Tab. 3: Ver Basetine 12 menths Charige 95% Cente 60 merchs 60 merchs 9 95% Cente	Tical Protein Polytacide 6.35-1.61 4.35:1.70 4.00:9.91 < 6.001 2.001 2.001 2.001 dence Interva 4.001 dence Interva	Attached a second a s		0.91 0.26 0.27 0.27
Tab. 5: Ver Baseline 12 reenths Change P 97% Cente 60 reenths 60 reenths 60 reenths 98% Center 93% Center	14231 Proteing Polylactide 6.35-1.61 4.35:170 4.35:170 4.35:091 ≪ 8.001 dense Interna \$49-187 2.38-100 ≪ 6.001 dense Interna 1.6221,00	Artoniaatio B 31::1 32 4 05::1 52 4 05::1 52 + 0.501 4 06:2 17 2::21::1 50 0.001	 Difference 0.64±1.20 0.54±1.80 0.54±1.83 0.54±1.83 0.12±1.70 0.15±1.84 	0.91 0.26 0.27 0.27
Tab. 3: Ver Basetine 12 menths Charige 95% Cente 60 merchs 60 merchs 9 95% Cente	1101 Proteing Polytacide 6.35:1.61 4.35:1.70 4.30:0.91 4.001 dence Interva 5.46:1.87 2.38:1.40 4.001 dence Interva 4.001 dence Interva 5.40:1.00 4.001 dence Interva 5.40:1.00	Attacture 8,31:=1,32 4,05:=55 3,40:=52 4,06:2,17 2,25:=1,80 0,60:1 -(,2):=1,93		0.91 0.26 0.27 0.27
Tab. 5: Ver Buschine 12 menths Change P 95% Cenths Change P 95% Cenths Change 12-60 ment P	14231 Proteing Polylactide 6.35-1.61 4.35:170 4.35:170 4.35:091 ≪ 8.001 dense Interna \$49-187 2.38-100 ≪ 6.001 dense Interna 1.6221,00	Attachment I Polydiataaror 8 31±1 32 4 051±54 3 46±1 52 + 0.501 4 06±2 17 2251±1 55 0.601 -(23±155) 4 0.601 -(23±155) 4 0.601		0.91
Tab. 5: Ver Buschine 12 menths Change P 95% Cenths Change P 95% Cenths Change 12-60 ment P	11(21) Proteing Polytactide 6.35:170 4.35:170 4.35:091 < 6.001 dense Interve \$ 646:187 2.31:100 < 6.001 dense Interve 142:130 dense Interve 142:130 dense 143:130	Attachment I Polydiataaror 8 31±1 32 4 051±54 3 46±1 52 + 0.501 4 06±2 17 2251±1 55 0.601 -(23±155) 4 0.601 -(23±155) 4 0.601	4440 441 12 0.04-1.20 0.04-1.20 0.054:1.33 0.54:1.60 0.15:1.00 0.15:1.00 0.15:1.00 0.15:1.00 0.15:1.00 0.15:1.00 0.001.27 0.001.27 0.001.27	0.91 0.26 0.27 0.27
Tab. 3. Ver Baseline 12 menths Charge 9 95% Cente Charge 95% Cente Charge 12-00 ment 9 95% Cente	Polytacticle 6.35±1.61 4.35±1.61 4.35±1.61 4.35±0.91 4.35±0.91 4.50±0.91 4.50±0.91 4.50±1.60 4.60±1 4.62±1.60 4.62±1	A15- Polydiosarov 6 31-1 32 4 051-1 32 4 051-1 52 1 0 501 4 08-2 17 2 224-1 80 0 001 4 001 2 224-1 80 0 001 2 224-1 80 0 001 0 000 0 000000	-1.744.97	0.51 0.25 0.27 0.61 0.77 0.51
Tab. 3. Ver Baschwe 12 menths Charge P 95% Cente Charge 95% Cente Charge 12 20 ment P 95% Cente	Tich Proteing Polylactide 6.35:17.0 4.02:05.0 4.05:05.00000000000000000000000000000000	Artschneet L Polydasarar 8 31-t 32 4 35-t 32 5-t 32	America 12 0 Citieringa 0 44:120 -0 56:130 0 56:130 0 54:189 -1 59-8.33 0 12:170 0 19:130 - 4 59-7.127 0 19:1326 - 4 39-6.97 - 1 34-8.97 - 1 34-8.97	0.91 0.25 0.27 0.81 0.51
Tab. 3. Ver Baschwe 12 menths Charge P 95% Cente Charge 95% Cente Charge 12 20 ment P 95% Cente	Polylactide 6.35-1.61 4.32-1.70 4.32-0.91 4.02-0.91 4.02-0.91 4.02-0.91 4.02-0.91 4.02-0.91 4.02-0.91 4.02-1.00 70 4.00-1 denos Intervo 4.00-1 denos Intervo 4.00-1 denos Intervo 4.00-1 denos Intervo	Arton meest 1 Polydiazaror 8 31-1 32 4 65: 1 53 - 0.201 0.001 (21)-1 52 - 0.001 (21)-1 52 - 0.001 (21)-1 52 - 0.001 (21)-1 53 - 0.001 (21)	America 12, 6 Difference 0.64:1,20 -0.56:1,31 0.54:1,89 -1.56:6,33 0.122:1,85 0.122:1,85 0.52:1,27 0.132:1,85 0.57-1,27 0.132:1,85 0.57-1,27 0.132:1,85 -1.34-6,97 9 African american amer	0.91 0.25 0.27 0.27 0.27 0.27
Tab 5 Ver Bisselive Charge 9 5% Centro 60 recents Charge β 95% Centro 12-00 meet 95% Centro 12-00 meet 95% Centro 12-00 meet 95% Centro 12-00 meet 12-00 meet 12-000	Tical Protocy Polytachia 6 35:151 6 43:151 70 4.92:6 91 4.92:6 91 4.92:6 91 4.92:6 91 4.92:100 4.92:10	Artushineen 1 Pelydeaanoo 4 51 - 1 2 4 55 - 1 54 3 - 6 50 1 4 - 6 50 1 5 - 6	America 12 0 Citieringa 0 44:120 -0 56:130 0 56:130 0 54:189 -1 59-8.33 0 12:170 0 19:130 - 4 59-7.127 0 19:1326 - 4 39-6.97 - 1 34-8.97 - 1 34-8.97	0.91 0.25 0.27 0.27 0.27 0.27
Tab 5 Ver Bisseitre Charge P 95% Centre 60 recents Charge P 95% Centre 12-20 ment P 95% Centre 12-20 ment P	Tech Protocol Polytacide 6 35-169 6 435-170 6 435-170 6 435-170 6 435-170 6 435-170 8 435-170 8 435-170 8 435-170 6 435-170 7 400-170 7	Arton ment 1 Polydosarno 8 (1) - 1 / 2 3 - 6 / 5 4 - 6 / 5 7 - 7 / 7 7 - 7 /	America 12, 6 Difference 0.64:1,20 -0.56:1,31 0.54:1,89 -1.56:6,33 0.122:1,85 0.122:1,85 0.52:1,27 0.132:1,85 0.57-1,27 0.132:1,85 0.57-1,27 0.132:1,85 -1.34-6,97 9 African american amer	0.91 0.25 0.27 0.27 0.27 0.27
Tab 1: Ver Baseline (La reprine P 95% Confu 60 months 60 months 60 months 60 months 93% Confu 1240 months 93% Confu 1240 confu 1240 confu 93% Confu 1240 confu 93% Confu 1240 co	Tical Protocy Polytacide 6 35-169 6 435-170 6 435-170 6 435-170 6 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 45-170 8 4	Artushineen 1 Pelydeaanoo 4 51 - 1 2 4 55 - 1 54 3 - 6 50 1 4 - 6 50 1 5 - 6	America 12, 6 Ofference 0.64:1,20 -0.56:1,31 0.54:1,89 -1.56:6,33 0.122:1,85 0.122:1,85 0.52:1,27 0.132:1,85 0.57-1,27 0.132:1,85 0.57-1,27 0.132:1,85 -1.34-6,97 9 Affective constraints	0.51 0.25 0.27 0.57 0.57 0.57
Tab 5 Ver Bisselive Charge 9 5% Centro 60 recents Charge β 95% Centro 12-00 meet 95% Centro 12-00 meet 95% Centro 12-00 meet 95% Centro 12-00 meet 12-00 meet 12-000	Tical Protocy Polytacide 6 35-169 6 435-170 6 435-170 6 435-170 6 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 45-170 8 4	Artushineeri Pelydesarror 4 51: 1: 54 3 45: 1: 54 3 45: 1: 54 3 45: 1: 54 3 45: 1: 54 4 6: 6: 54 5 7: 54 5	America 12, 6 Ofference 0.64:1,20 -0.56:1,31 0.54:1,89 -1.56:6,33 0.122:1,85 0.122:1,85 0.52:1,27 0.132:1,85 0.57-1,27 0.132:1,85 0.57-1,27 0.132:1,85 -1.34-6,97 9 Affective constraints	0.51 0.25 0.27 0.57 0.57 0.57 0.57
Tab 1: Ver Baseline (La reprine P 95% Confu 60 months 60 months 60 months 60 months 93% Confu 1240 months 93% Confu 1240 confu 1240 confu 93% Confu 1240 confu 93% Confu 1240 co	Tical Protocy Polytacide 6 35-169 6 435-170 6 435-170 6 435-170 6 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 435-170 8 45-170 8 4	Artushineeri Pelydesarror 4 51: 1: 54 3 45: 1: 54 3 45: 1: 54 3 45: 1: 54 3 45: 1: 54 4 6: 6: 54 5 7: 54 5	America 12, 6 Ofference 0.64:1,20 -0.56:1,31 0.54:1,89 -1.56:6,33 0.122:1,85 0.122:1,85 0.52:1,27 0.132:1,85 0.57-1,27 0.132:1,85 0.57-1,27 0.132:1,85 -1.34-6,97 9 Affective constraints	0.51 0.25 0.27 0.57 0.57 0.57 0.57
Табь 3: Ver Валейте 12 портип (Сланде р 95% Согла 60 портип 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 95%	Control Proteing Paylacticle Sist 14	Artushineeri Pelydesarror 4 51: 1: 54 3 45: 1: 54 3 45: 1: 54 3 45: 1: 54 3 45: 1: 54 4 6: 6: 54 5 7: 54 5	9 00 00 00 00 00 00 00 00 00 00 00 00 00	0.91 0.25 0.37 0.61 0.54 0.54
Табь 3: Ver Валейте 12 портип (Сланде р 95% Согла 60 портип 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 7 95% Согла 95%	ILCII Proteing Polytactide 6.35:140 4.35:170 4.35:170 4.35:170 4.35:170 4.35:170 4.35:170 4.35:170 4.35:170 4.35:170 4.35:170 4.35 4.5	Afactorent I Pelydosarrov 4 51-c 132 4 65-c 152 4 60-c 12 2 237-c 180 0.001 (210154) 4 00-c 12 2 237-c 180 0.001 (210154) 4 00-c 12 0.001 (210154) 4 00-c 12 0.0001 (210154) 4 00-c 12 0.001 (210154) 4 00-c 12 0.001 (210154) 6 00-c 12 0.001 (210154) 7 00-c 12 0.001 (2101555) 7 00-c 12 0.001 (2101555) 7 00-c 12 0.001 (2100555) 7 00-c 12 0.001 (210055555) 7 00-c 12 0.000 (210055555555555555555555555555555555555	energian (2) # Difference 0.64±130 0.64±130 0.54±169 1.55633 0.152130 0.15210 0.152130	0.91 0.25 0.37 0.61 0.51 0.51 0.51
Tab. 1: Ver Baseline 12 mention (Chasge P 95% Cerrite 60 mention P 95% Cerrite 7 95% C	1103 Protess Polytactide 6 35:147 4 35:147 4 35:147 4 35:147 4 35:147 2 35:	Attorney (1) Performance 4 501 - 13 4 501 - 50 5 501 - 50 5 6 501 6 6 501 (2) 11 50 6 6 501 (2) 11 50 6 6 501 (2) 11 50 6 6 501 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	Americana I.S. 0 Eliferences 0 Seri 320 0 Seri 320	0 51 0 35 0 37 0 51 0 51 0 51 0 51 0 51 0 51 0 51 0 51
Tab. 5. Ver Baselive 12 neerbin Chasge P 93% Certify 60 neorbin Change P 93% Certify 12-20 mer 93% Certify 12-20 mer 93% Certify 73% Certify 74% Certi	1103 Protess Polytactide 6 35: 154 4 35: 170 4 43: 170 4	Attor means 1. Poly disarray 8, 51 - 52 3, 66 - 52 4, 608 - 2, 17 2, 23 - 18 4, 608 - 2, 17 2, 24 - 18 4, 608 - 2, 17 2, 18 4, 184, 18 4, 18 4, 18 4, 18 4, 1	American 12, a Differences 0 64:120 0 50:133 0 54:120 0 54:120 0 120:120 0 1	0.91 0.35 0.37 0.81 0.11 0.94 0.94 0.94
Tab. 5. Ver Baseline 12 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 7 ab. 6. Dia 93% Centle 93% Centle 93% Centle 93% Centle 93% Centle 7 ab. 6. Dia 7 ab. 7. Dia	Inc.) Provides Polytacidate 4.90-0 91 4.90-0 91	Artor market 1 Performant 1 4 55:1 52 4 5:1 52 5 5:1 52	Americana III Medicana III Differences Spirit 30 Spirit 30 Sp	0.51 0.25 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31
Tab. 5. Ver Baselive 12 neerbin Chasge P 93% Certify 60 neorbin Change P 93% Certify 12-20 mer 93% Certify 12-20 mer 93% Certify 73% Certify 74% Certi	Inc. Provides provides 0.35-1570 0.35-1570 0.35-1570 0.25.05 97 0.05.05 0.05 0.05 0.05 0.05 0.05 0.05	Arton meet 1 Poly diseases 4 55 : 1 52 4 55 : 1 55 4 55 : 1 55 : 1 55 4 55 : 1 55 : 1 55 : 1 55 4 55 : 1	American 12, a Differences 0 64:120 0 50:133 0 54:120 0 54:120 0 120:120 0 1	0.91 0.35 0.37 0.81 0.11 0.94 0.94 0.94
Tab. 5. Ver Baseline 12 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 60 neerbin 7 ab. 6. Dia 93% Centle 93% Centle 93% Centle 93% Centle 93% Centle 7 ab. 6. Dia 7 ab. 7. Dia	Inc.) Provides Polytacidate 4.90-0 91 4.90-0 91	Artor market 1 Performant 1 4 55:1 52 4 5:1 52 5 5:1 52	Americana III Medicana III Differences Spirit 30 Spirit 30 Sp	0.51 0.25 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31